U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H24N4O2
Molecular Weight 340.4202
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PENTAMIDINE

SMILES

C(CCOc1ccc(cc1)C(=N)N)CCOc2ccc(cc2)C(=N)N

InChI

InChIKey=XDRYMKDFEDOLFX-UHFFFAOYSA-N
InChI=1S/C19H24N4O2/c20-18(21)14-4-8-16(9-5-14)24-12-2-1-3-13-25-17-10-6-15(7-11-17)19(22)23/h4-11H,1-3,12-13H2,(H3,20,21)(H3,22,23)

HIDE SMILES / InChI

Molecular Formula C19H24N4O2
Molecular Weight 340.4202
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: description was created based on several sources, including: http://www.drugbank.ca/drugs/DB00738 https://en.wikipedia.org/wiki/Pentamidine

Pentamidine (formulated as a salt, pentamidine diisethionate or dimesilate) is an antimicrobial medication given for prevention and treatment of pneumocystis pneumonia (PCP) caused by Pneumocystis jirovecii (formerly known as Pneumocystis carinii), a severe interstitial type of pneumonia often seen in patients with HIV infection. The drug is also the mainstay of treatment for stage I infection with Trypanosoma bruceigambiense (West African trypanosomiasis). Pentamidine is also used as a prophylactic against PCP in patients receiving chemotherapy and in some patients who have undergone organ transplantation, as they also have a depressed immune system as a direct side-effect of the drugs used. The mortality of untreated PCP is very high. Additionally, pentamidine has good clinical activity in treating leishmaniasis, and yeast infections caused by the organism Candida albicans. Pentamidine is also used as a prophylactic antibiotic for children undergoing treatment for leukemia. Studies suggest that the pentamidine isethionate interferes with microbial nuclear metabolism by inhibition of DNA, RNA, phospholipid and protein synthesis. However, the mode of action is not fully understood.

CNS Activity

Curator's Comment:: Pentamidine is able to cross the BBB, but a proportion is retained within the capillary endothelium. This may well explain its inability to treat well established CNS trypanosome infection. Furthermore, pentamidine movement into the CNS is a complex process involving multiple transporters.

Originator

Curator's Comment:: Pentamidine was first discovered by Ewins et al., as shown in U.S. Patent No. 2,277,861

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: O14717
Gene ID: 1787.0
Gene Symbol: TRDMT1
Target Organism: Homo sapiens (Human)
204.4 µM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
NEBUPENT

Approved Use

Pentamidine

Launch Date

4.82112012E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
751 nM
3.9 mg/kg 1 times / day multiple, intravenous
dose: 3.9 mg/kg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
PENTAMIDINE blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
18.8 ng/mL
4 mg/kg 1 times / day multiple, irrigation
dose: 4 mg/kg
route of administration: Irrigation
experiment type: MULTIPLE
co-administered:
PENTAMIDINE unknown
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
612 ng/mL
4 mg/kg single, intravenous
dose: 4 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PENTAMIDINE unknown
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
6734 nM × h
3.9 mg/kg 1 times / day multiple, intravenous
dose: 3.9 mg/kg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
PENTAMIDINE blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
6.4 h
4 mg/kg single, intravenous
dose: 4 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PENTAMIDINE unknown
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1600 mg single, intravenous
Overdose
unhealthy, 17
n = 1
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Age Group: 17
Population Size: 1
Sources:
Other AEs: Impaired renal function, Hepatic impairment...
Other AEs:
Impaired renal function
Hepatic impairment
Hypotension
Cardiopulmonary arrest
Sources:
600 mg 1 times / month multiple, respiratory
Highest studied dose
Dose: 600 mg, 1 times / month
Route: respiratory
Route: multiple
Dose: 600 mg, 1 times / month
Sources: Page: p.1167
unhealthy, 37.9 ± 7.5
n = 76
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Age Group: 37.9 ± 7.5
Sex: M+F
Population Size: 76
Sources: Page: p.1167
300 mg 1 times / month multiple, respiratory
Recommended
Dose: 300 mg, 1 times / month
Route: respiratory
Route: multiple
Dose: 300 mg, 1 times / month
Sources: Page: p.6
unhealthy
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Sources: Page: p.6
Disc. AE: Acute pancreatitis...
AEs leading to
discontinuation/dose reduction:
Acute pancreatitis
Sources: Page: p.6
4 mg/kg 1 times / day multiple, intramuscular
Recommended
Dose: 4 mg/kg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 4 mg/kg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Sources:
Disc. AE: Hypotension, Hypoglycemia...
Other AEs: Extravasation, Injection site ulceration...
AEs leading to
discontinuation/dose reduction:
Hypotension (grade 3-5)
Hypoglycemia (grade 5)
Acute pancreatitis (grade 5)
Cardiac arrhythmias (grade 5)
Cardiac arrhythmias (grade 5)
Other AEs:
Extravasation
Injection site ulceration
Injection site necrosis
Slough injection site
Sources:
4 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 4 mg/kg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Sources:
Disc. AE: Hypotension, Hypoglycemia...
Other AEs: Extravasation, Injection site ulceration...
AEs leading to
discontinuation/dose reduction:
Hypotension (grade 3-5)
Hypoglycemia (grade 5)
Acute pancreatitis (grade 5)
Cardiac arrhythmias (grade 5)
Cardiac arrhythmias (grade 5)
Other AEs:
Extravasation
Injection site ulceration
Injection site necrosis
Slough injection site
Sources:
AEs

AEs

AESignificanceDosePopulation
Cardiopulmonary arrest
1600 mg single, intravenous
Overdose
unhealthy, 17
n = 1
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Age Group: 17
Population Size: 1
Sources:
Hepatic impairment
1600 mg single, intravenous
Overdose
unhealthy, 17
n = 1
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Age Group: 17
Population Size: 1
Sources:
Hypotension
1600 mg single, intravenous
Overdose
unhealthy, 17
n = 1
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Age Group: 17
Population Size: 1
Sources:
Impaired renal function
1600 mg single, intravenous
Overdose
unhealthy, 17
n = 1
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Age Group: 17
Population Size: 1
Sources:
Acute pancreatitis Disc. AE
300 mg 1 times / month multiple, respiratory
Recommended
Dose: 300 mg, 1 times / month
Route: respiratory
Route: multiple
Dose: 300 mg, 1 times / month
Sources: Page: p.6
unhealthy
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Sources: Page: p.6
Extravasation
4 mg/kg 1 times / day multiple, intramuscular
Recommended
Dose: 4 mg/kg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 4 mg/kg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Sources:
Injection site necrosis
4 mg/kg 1 times / day multiple, intramuscular
Recommended
Dose: 4 mg/kg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 4 mg/kg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Sources:
Injection site ulceration
4 mg/kg 1 times / day multiple, intramuscular
Recommended
Dose: 4 mg/kg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 4 mg/kg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Sources:
Slough injection site
4 mg/kg 1 times / day multiple, intramuscular
Recommended
Dose: 4 mg/kg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 4 mg/kg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Sources:
Hypotension grade 3-5
Disc. AE
4 mg/kg 1 times / day multiple, intramuscular
Recommended
Dose: 4 mg/kg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 4 mg/kg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Sources:
Acute pancreatitis grade 5
Disc. AE
4 mg/kg 1 times / day multiple, intramuscular
Recommended
Dose: 4 mg/kg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 4 mg/kg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Sources:
Cardiac arrhythmias grade 5
Disc. AE
4 mg/kg 1 times / day multiple, intramuscular
Recommended
Dose: 4 mg/kg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 4 mg/kg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Sources:
Cardiac arrhythmias grade 5
Disc. AE
4 mg/kg 1 times / day multiple, intramuscular
Recommended
Dose: 4 mg/kg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 4 mg/kg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Sources:
Hypoglycemia grade 5
Disc. AE
4 mg/kg 1 times / day multiple, intramuscular
Recommended
Dose: 4 mg/kg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 4 mg/kg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Sources:
Extravasation
4 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 4 mg/kg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Sources:
Injection site necrosis
4 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 4 mg/kg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Sources:
Injection site ulceration
4 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 4 mg/kg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Sources:
Slough injection site
4 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 4 mg/kg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Sources:
Hypotension grade 3-5
Disc. AE
4 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 4 mg/kg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Sources:
Acute pancreatitis grade 5
Disc. AE
4 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 4 mg/kg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Sources:
Cardiac arrhythmias grade 5
Disc. AE
4 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 4 mg/kg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Sources:
Cardiac arrhythmias grade 5
Disc. AE
4 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 4 mg/kg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Sources:
Hypoglycemia grade 5
Disc. AE
4 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 4 mg/kg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Pneumonia due to Pneumocystis carinii
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer




Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes [IC50 0.097 uM]
yes
Drug as victim
PubMed

PubMed

TitleDatePubMed
[Kidney failure during treatment of T. rhodesiense trypanosomiasis with pentamidin].
1977
[Nephrotoxic effect of pentamidine in the treatment of interstitial pneumonia in 2 children with acute lymphoblastic leukemia].
1979 Dec
Extrapyramidal symptoms in AIDS patients given low-dose metoclopramide or chlorpromazine.
1985 Nov 23
Pentamidine and hematuria.
1986 Jul
Adverse reactions associated with pentamidine isethionate in AIDS patients: recommendations for monitoring therapy.
1986 Nov
Recurrent ventricular tachycardia due to pentamidine-induced cardiotoxicity.
1988 Dec
Cationic antitrypanosomal and other antimicrobial agents in the therapy of experimental Pneumocystis carinii pneumonia.
1988 Jun
Torsades de pointes during intravenous pentamidine isethionate therapy.
1989 Jan 15
Pentamidine-induced torsades de pointes in a renal transplant recipient with Pneumocystis carinii pneumonia.
1990 Apr
Analogues of 1,5-bis(4-amidinophenoxy)pentane (pentamidine) in the treatment of experimental Pneumocystis carinii pneumonia.
1990 Apr
Effects of pentamidine alone and in combination with ketoconazole or itraconazole on the growth of Candida albicans.
1990 Dec
Novel pentamidine analogs in the treatment of experimental Pneumocystis carinii pneumonia.
1990 Jun
Acute, rapidly progressive renal failure with simultaneous use of amphotericin B and pentamidine.
1990 Mar
Symptomatic hypocalcemia and hypomagnesemia with renal magnesium wasting associated with pentamidine therapy in a patient with AIDS.
1990 Sep
Pentamidine-associated nephrotoxicity and hyperkalemia in patients with AIDS.
1991 Nov
Anti-cryptosporidial drug activity screened with an immunosuppressed rat model.
1991 Nov-Dec
Cardiac arrest during treatment of Pneumocystis carinii pneumonia with intravenous pentamidine isethionate.
1992
High pentamidine levels associated with hypoglycemia and azotemia in a patient with Pneumocystis carinii pneumonia.
1992 Aug
Hematuria associated with pentamidine therapy for Pneumocystis carinii pneumonia.
1992 Jun
Torsade de pointes after inhaled pentamidine.
1992 Nov
Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs.
1992 Sep
Synthesis and anti-Pneumocystis carinii pneumonia activity of novel dicationic dibenzothiophenes and orally active prodrugs.
1999 Jul-Aug
[American cutaneous leishmaniasis in the Federal District].
1999 Sep-Oct
Serum neopterin concentrations during treatment of leishmaniasis: useful as test of cure?
2000 Jan
Prophylactic effect of FK463, a novel antifungal lipopeptide, against Pneumocystis carinii infection in mice.
2000 Sep
[Human African trypanosomiasis from Trypanosoma brucei gambiense with inoculation chancre in a French expatriate].
2001
Pentamidine isethionate as treatment and secondary prophylaxis for disseminated cutaneous leishmaniasis during HIV infection: case report.
2001 Dec
Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s.
2001 Jan
Anti-human immunodeficiency virus drugs are ineffective against Pneumocystis carinii in vitro and in vivo.
2001 Nov 15
[Rhabdomyolysis induced by pentamidine (Pentacarinat) during treatment of cutaneous leishmaniasis: 2 cases].
2002 Jan
Intravenous pentamidine induced megaloblastic anaemia.
2002 Jan
In vitro activities of pentamidine, pyrimethamine, trimethoprim, and sulfonamides against Aspergillus species.
2002 Jun
A reverse turn structure induced by a D,L-alpha-aminoxy acid dimer.
2003 Nov 26
New agents active against Mycobacterium avium complex selected by molecular topology: a virtual screening method.
2004 Jan
Pentamidine-induced long QT syndrome and block of hERG trafficking.
2005 Jan
Detection of immunotoxicity using T-cell based cytokine reporter cell lines ("Cell Chip").
2005 Jan 15
Protein trafficking abnormalities: a new mechanism in drug-induced long QT syndrome.
2005 May
[Cutaneous leishmaniasis--an import from Belize].
2007
Perioral numbness associated with intravenous pentamidine administration.
2007 Jan
Cellulose biosynthesis pathway is a potential target in the improved treatment of Acanthamoeba keratitis.
2007 May
Pentamidine dosage: a base/salt confusion.
2008 May 28
Synthesis and antiprotozoal activity of pyridyl analogues of pentamidine.
2009 Aug 13
Identification of human Ether-à-go-go related gene modulators by three screening platforms in an academic drug-discovery setting.
2010 Dec
Bisbenzamidine derivative, pentamidine represses DNA damage response through inhibition of histone H2A acetylation.
2010 Feb 9
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
2011 Jul 14
Synthetic chromanol derivatives and their interaction with complex III in mitochondria from bovine, yeast, and Leishmania.
2011 Oct 17
Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model.
2013 Dec
Synthesis and antiprotozoal activities of benzyl phenyl ether diamidine derivatives.
2013 Sep
Utilization of human nuclear receptors as an early counter screen for off-target activity: a case study with a compendium of 615 known drugs.
2015 Jun
Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.
2015 May 18
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: 300 mg once every four weeks administered via the Respirgard
The recommended adult dosage is 300 mg once every four weeks administered via the Respirgard® II nebulizer. The dose should be delivered until the nebulizer chamber is empty (approximately 30 to 45 minutes). The flow rate should be 5 to 7 liters per minute from a 40 to 50 pounds per square inch (PSI) air or oxygen source. Alternatively, a 40 to 50 PSI air compressor can be used with flow limited by setting the flowmeter at 5 to 7 liters per minute or by setting the pressure at 22 to 25 PSI. Low pressure (less than 20 PSI) compressors should not be used.
Route of Administration: Irrigation
In Vitro Use Guide
Pentamidine was found to be active against T. whipplei strains both in axenic medium and in cell culture, with minimum inhibitory concentration ranges of 0.125-0.25mg/L.
Substance Class Chemical
Created
by admin
on Sat Jun 26 00:18:13 UTC 2021
Edited
by admin
on Sat Jun 26 00:18:13 UTC 2021
Record UNII
673LC5J4LQ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PENTAMIDINE
HSDB   INN   MI   VANDF   WHO-DD  
INN  
Official Name English
NSC-9921
Code English
RP-2512 FREE BASE
Code English
PENTAM 300
Brand Name English
PENTAMIDINE [WHO-DD]
Common Name English
MB-800
Code English
PENTAMIDINE [VANDF]
Common Name English
4,4'-(PENTAMETHYLENEDIOXY)DIBENZAMIDINE
Systematic Name English
RP-2512
Code English
RP 2512 FREE BASE
Code English
MP-601205
Common Name English
PENTAMIDINE [MI]
Common Name English
MB 800 FREE BASE
Code English
PENTAMIDINE [INN]
Common Name English
MB-800 FREE BASE
Code English
MB-800 (AS ISETHIONATE)
Code English
PENTAMIDINE [HSDB]
Common Name English
Classification Tree Code System Code
WHO-ATC P01CX01
Created by admin on Sat Jun 26 00:18:13 UTC 2021 , Edited by admin on Sat Jun 26 00:18:13 UTC 2021
FDA ORPHAN DRUG 279709
Created by admin on Sat Jun 26 00:18:13 UTC 2021 , Edited by admin on Sat Jun 26 00:18:13 UTC 2021
WHO-VATC QP51AF02
Created by admin on Sat Jun 26 00:18:13 UTC 2021 , Edited by admin on Sat Jun 26 00:18:13 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.5.5.1
Created by admin on Sat Jun 26 00:18:13 UTC 2021 , Edited by admin on Sat Jun 26 00:18:13 UTC 2021
NDF-RT N0000175485
Created by admin on Sat Jun 26 00:18:13 UTC 2021 , Edited by admin on Sat Jun 26 00:18:13 UTC 2021
NCI_THESAURUS C514
Created by admin on Sat Jun 26 00:18:13 UTC 2021 , Edited by admin on Sat Jun 26 00:18:13 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.5.4
Created by admin on Sat Jun 26 00:18:13 UTC 2021 , Edited by admin on Sat Jun 26 00:18:13 UTC 2021
FDA ORPHAN DRUG 389312
Created by admin on Sat Jun 26 00:18:13 UTC 2021 , Edited by admin on Sat Jun 26 00:18:13 UTC 2021
FDA ORPHAN DRUG 389212
Created by admin on Sat Jun 26 00:18:13 UTC 2021 , Edited by admin on Sat Jun 26 00:18:13 UTC 2021
LIVERTOX 755
Created by admin on Sat Jun 26 00:18:13 UTC 2021 , Edited by admin on Sat Jun 26 00:18:13 UTC 2021
NCI_THESAURUS C277
Created by admin on Sat Jun 26 00:18:13 UTC 2021 , Edited by admin on Sat Jun 26 00:18:13 UTC 2021
Code System Code Type Description
MERCK INDEX
M8497
Created by admin on Sat Jun 26 00:18:13 UTC 2021 , Edited by admin on Sat Jun 26 00:18:13 UTC 2021
PRIMARY Merck Index
MESH
D010419
Created by admin on Sat Jun 26 00:18:13 UTC 2021 , Edited by admin on Sat Jun 26 00:18:13 UTC 2021
PRIMARY
WIKIPEDIA
PENTAMIDINE
Created by admin on Sat Jun 26 00:18:13 UTC 2021 , Edited by admin on Sat Jun 26 00:18:13 UTC 2021
PRIMARY
CAS
100-33-4
Created by admin on Sat Jun 26 00:18:13 UTC 2021 , Edited by admin on Sat Jun 26 00:18:13 UTC 2021
PRIMARY
INN
4167
Created by admin on Sat Jun 26 00:18:13 UTC 2021 , Edited by admin on Sat Jun 26 00:18:13 UTC 2021
PRIMARY
EPA CompTox
100-33-4
Created by admin on Sat Jun 26 00:18:13 UTC 2021 , Edited by admin on Sat Jun 26 00:18:13 UTC 2021
PRIMARY
DRUG CENTRAL
2090
Created by admin on Sat Jun 26 00:18:13 UTC 2021 , Edited by admin on Sat Jun 26 00:18:13 UTC 2021
PRIMARY
RXCUI
7994
Created by admin on Sat Jun 26 00:18:13 UTC 2021 , Edited by admin on Sat Jun 26 00:18:13 UTC 2021
PRIMARY RxNorm
ECHA (EC/EINECS)
202-841-0
Created by admin on Sat Jun 26 00:18:13 UTC 2021 , Edited by admin on Sat Jun 26 00:18:13 UTC 2021
PRIMARY
NCI_THESAURUS
C731
Created by admin on Sat Jun 26 00:18:13 UTC 2021 , Edited by admin on Sat Jun 26 00:18:13 UTC 2021
PRIMARY
ChEMBL
CHEMBL55
Created by admin on Sat Jun 26 00:18:13 UTC 2021 , Edited by admin on Sat Jun 26 00:18:13 UTC 2021
PRIMARY
HSDB
7474
Created by admin on Sat Jun 26 00:18:13 UTC 2021 , Edited by admin on Sat Jun 26 00:18:13 UTC 2021
PRIMARY
FDA UNII
673LC5J4LQ
Created by admin on Sat Jun 26 00:18:13 UTC 2021 , Edited by admin on Sat Jun 26 00:18:13 UTC 2021
PRIMARY
EVMPD
SUB09682MIG
Created by admin on Sat Jun 26 00:18:13 UTC 2021 , Edited by admin on Sat Jun 26 00:18:13 UTC 2021
PRIMARY
DRUG BANK
DB00738
Created by admin on Sat Jun 26 00:18:13 UTC 2021 , Edited by admin on Sat Jun 26 00:18:13 UTC 2021
PRIMARY
PUBCHEM
4735
Created by admin on Sat Jun 26 00:18:13 UTC 2021 , Edited by admin on Sat Jun 26 00:18:13 UTC 2021
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
TRANSPORTER -> INHIBITOR
SALT/SOLVATE -> PARENT
TRANSPORTER -> INHIBITOR
TRANSPORTER -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY